Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zachariae

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|September 2, 2005
The effect of spiritual healing on in vitro tumour cell proliferation and viability--an experimental studyR Zachariae, L Højgaard, C Zachariae, et al.
Contact Dermatitis|May 1, 1989
ETAF/interleukin-1 and epidermal lymphocyte chemotactic factor in epidermis overlying an irritant patch testC Grønhøj Larsen, T Ternowitz, F Grønhøj Larsen, et al.
Clinical Oral Investigations|January 14, 2017
Symptomatic oral lesions may be associated with contact allergy to substances in oral hygiene productsK R Larsen, J D Johansen, J Reibel, et al.
The Journal of Allergy and Clinical Immunology|May 1, 1995
Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytesT Jinquan, C M Reimert, B Deleuran, et al.
Journal of Internal Medicine|July 16, 2015
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasisM Gyldenløve, T Vilsbøll, C Zachariae, et al.
The British Journal of Dermatology|March 31, 2015
Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasisM Gyldenløve, T Vilsbøll, J J Holst, et al.
Progress in Clinical and Biological Research|January 1, 1990
Proinflammatory cytokines interleukin 1 and tumor necrosis factor induce cytokines that are chemotactic for neutrophils, T cells and monocytesC Larsen, C Zachariae, N Mukaida, et al.
Acta Diabetologica|December 14, 2011
Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutideA Faurschou, F K Knop, J P Thyssen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 29, 2020
Clinical characteristics including cardiovascular and metabolic risk factors in adolescents with psoriasisC Blegvad, A-M Nybo Andersen, J Groot, et al.
The British Journal of Dermatology|January 25, 2019
Localization of treatment-resistant areas in patients with psoriasis on biologicsK F Hjuler, L Iversen, M K Rasmussen, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|September 2, 2005
The effect of spiritual healing on in vitro tumour cell proliferation and viability--an experimental studyR Zachariae, L Højgaard, C Zachariae, et al.
Contact Dermatitis|May 1, 1989
ETAF/interleukin-1 and epidermal lymphocyte chemotactic factor in epidermis overlying an irritant patch testC Grønhøj Larsen, T Ternowitz, F Grønhøj Larsen, et al.
Clinical Oral Investigations|January 14, 2017
Symptomatic oral lesions may be associated with contact allergy to substances in oral hygiene productsK R Larsen, J D Johansen, J Reibel, et al.
The Journal of Allergy and Clinical Immunology|May 1, 1995
Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytesT Jinquan, C M Reimert, B Deleuran, et al.
Journal of Internal Medicine|July 16, 2015
Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasisM Gyldenløve, T Vilsbøll, C Zachariae, et al.
The British Journal of Dermatology|March 31, 2015
Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasisM Gyldenløve, T Vilsbøll, J J Holst, et al.
Progress in Clinical and Biological Research|January 1, 1990
Proinflammatory cytokines interleukin 1 and tumor necrosis factor induce cytokines that are chemotactic for neutrophils, T cells and monocytesC Larsen, C Zachariae, N Mukaida, et al.
Acta Diabetologica|December 14, 2011
Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutideA Faurschou, F K Knop, J P Thyssen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 29, 2020
Clinical characteristics including cardiovascular and metabolic risk factors in adolescents with psoriasisC Blegvad, A-M Nybo Andersen, J Groot, et al.
The British Journal of Dermatology|January 25, 2019
Localization of treatment-resistant areas in patients with psoriasis on biologicsK F Hjuler, L Iversen, M K Rasmussen, et al.
Pageof 8